Compositions and methods of treatment of Ehlers-Danlos syndromes

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Get Citations Add to Saved list
  • Publication Date:
    January 31, 2023
  • Additional Information
    • Patent Number:
      11564,958
    • Appl. No:
      16/956469
    • Application Filed:
      December 21, 2018
    • Abstract:
      A method is provided for treatment of symptoms of Ehlers-Danlos Syndromes comprising administration of a composition comprising rubeola virus, histamine and collagen.
    • Inventors:
      RESOLYS BIO, INC. (Delanson, NY, US)
    • Assignees:
      RESOLYS BIO, INC. (Delanson, NY, US)
    • Claim:
      1. A method of treating symptoms of an Ehlers-Danlos Syndrome in a subject suffering therefrom comprising the step of administering to said subject an effective amount of a composition comprising rubeola virus, histamine and collagen wherein the symptom is selected from the group consisting of fatigue, range of motion and emesis.
    • Claim:
      2. The method of claim 1 wherein the Ehlers-Danlos Syndrome is selected from the group of hypermobile EDS (hEDS) and classical EDS (cEDS).
    • Claim:
      3. The method of claim 1 wherein the Ehlers-Danlos Syndrome is hypermobile EDS (hEDS).
    • Claim:
      4. The method of claim 1 wherein the composition comprises rubeola virus in a dosage of from 0.4 TCID 50 to 400 TCID 50 .
    • Claim:
      5. The method of claim 1 wherein the composition comprises histamine in a dosage of from 0.001 mg to 0.1 mg.
    • Claim:
      6. The method of claim 1 wherein the histamine is a water soluble histamine salt.
    • Claim:
      7. The method of claim 1 wherein the histamine is histamine phosphate.
    • Claim:
      8. The method of claim 1 wherein the composition comprises collagen in a dosage of from 0.0001 mg to 0.1 mg.
    • Claim:
      9. The method of claim 1 wherein the composition further comprises Immunoglobulin.
    • Claim:
      10. The method of claim 9 wherein the composition comprises Immunoglobulin in a dosage of from 0.0001 mg to 0.3 mg.
    • Claim:
      11. The method of claim 9 in which the immunoglobulin is human immunoglobulin.
    • Claim:
      12. The method of claim 9 in which the immunoglobulin is IgG.
    • Claim:
      13. The method of claim 4 in which the composition comprises rubeola virus in a dosage of from 1 TCID 50 to 10 TCID 50 .
    • Claim:
      14. The method of claim 5 in which the composition comprises histamine in a dosage of from 0.01 mg to 0.05 mg.
    • Claim:
      15. The method of claim 8 in which the composition comprises collagen in a dosage of from 0.001 mg to 0.01 mg.
    • Claim:
      16. The method of claim 10 in which the composition comprises immunoglobulin in a dosage of from 0.001 mg to 0.03 mg.
    • Patent References Cited:
      4704273 November 1987 McMichael
      20050261250 November 2005 Daifotis et al.
      20160185842 June 2016 Marotta et al.
    • Other References:
      European Patent Application No. 18891544.1, Extended European Search Report, dated Jun. 21, 2021. cited by applicant
    • Primary Examiner:
      Weddington, Kevin E
    • Attorney, Agent or Firm:
      Marshall, Gerstein & Borun LLP
    • Accession Number:
      edspgr.11564958
  • Citations
    • ABNT:
      RESOLYS BIO, I. (Delanson, N. Compositions and methods of treatment of Ehlers-Danlos syndromes. [s. l.], 2023. Disponível em: https://ezproxy.mscc.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edspgr&AN=edspgr.11564958. Acesso em: 1 abr. 2023.
    • AMA 11th Edition:
      RESOLYS BIO I (Delanson, N. Compositions and methods of treatment of Ehlers-Danlos syndromes. 20230131 2023. Accessed April 1, 2023. https://ezproxy.mscc.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edspgr&AN=edspgr.11564958
    • APA 7th Edition:
      RESOLYS BIO, I. (Delanson, N. (2023). Compositions and methods of treatment of Ehlers-Danlos syndromes.
    • Chicago 17th Edition:
      RESOLYS BIO, INC. (Delanson, NY). 2023. “Compositions and Methods of Treatment of Ehlers-Danlos Syndromes.” https://ezproxy.mscc.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edspgr&AN=edspgr.11564958.
    • Harvard:
      RESOLYS BIO, I. (Delanson, N. (2023) ‘Compositions and methods of treatment of Ehlers-Danlos syndromes’. Available at: https://ezproxy.mscc.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edspgr&AN=edspgr.11564958 (Accessed: 1 April 2023).
    • Harvard: Australian:
      RESOLYS BIO, I (Delanson, N 2023, ‘Compositions and methods of treatment of Ehlers-Danlos syndromes’, viewed 1 April 2023, .
    • MLA 9th Edition:
      RESOLYS BIO, INC.(Delanson, NY). Compositions and Methods of Treatment of Ehlers-Danlos Syndromes. 20230131 2023. EBSCOhost, ezproxy.mscc.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edspgr&AN=edspgr.11564958.
    • Chicago 17th Edition:
      RESOLYS BIO, INC. (Delanson, NY). “Compositions and Methods of Treatment of Ehlers-Danlos Syndromes,” 20230131 2023. https://ezproxy.mscc.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edspgr&AN=edspgr.11564958.
    • Vancouver/ICMJE:
      RESOLYS BIO I (Delanson, N. Compositions and methods of treatment of Ehlers-Danlos syndromes. 2023 20230131 [cited 2023 Apr 1]; Available from: https://ezproxy.mscc.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edspgr&AN=edspgr.11564958